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Abstract
Polycyclic aromatic hydrocarbons (PAH) are potent
mammary carcinogens in rodents, but their effect on
breast cancer development in women is not clear. To
examine whether currently measurable PAH damage to
DNA increases breast cancer risk, a population-based
case-control study was undertaken on Long Island, NY.
Cases were women newly diagnosed with in situ and
invasive breast cancer; controls were randomly selected
women frequency matched to the age distribution of
cases. Blood samples were donated by 1102 (73.0%)
and 1141 (73.3%) of case and control respondents,
respectively. Samples from 576 cases and 427 controls
were assayed for PAH-DNA adducts using an ELISA.
The geometric mean (and geometric SD) of the log-
transformed levels of PAH-DNA adducts on a natural
scale was slightly, but nonsignificantly, higher among
cases [7.36 (7.29)] than among controls [6.21 (4.17); P 
0.51]. The age-adjusted odds ratio (OR) for breast cancer
in relation to the highest quintile of adduct levels
compared with the lowest was 1.51 [95% confidence
interval (CI), 1.04–2.20], with little or no evidence of
substantial confounding (corresponding multivariate-
adjusted OR, 1.49; 95% CI, 1.00–2.21). There was no
consistent elevation in risk with increasing adduct levels,
nor was there a consistent association between adduct
levels and two of the main sources of PAH, active or
passive cigarette smoking or consumption of grilled and
smoked foods. These data indicate that PAH-DNA adduct
formation may influence breast cancer development,
although the association does not appear to be dose
dependent and may have a threshold effect.
Introduction
As in other areas of the United States, breast cancer is the most
commonly reported cancer among women who reside on Long
Island, NY. The high incidence rates observed in this geo-
graphic region3 (1) coupled with the local community’s long-
term concern about the health and ecological effects of envi-
ronmental pollution (2), have culminated in grass roots support
for the hypothesis that environmental pollutants are involved in
the development of breast cancer. This hypothesis is supported
by laboratory-based scientific evidence, as discussed in several
recent reviews (3, 4), although environmental agents other than
radiation (5) or use of alcohol (6, 7) have not been consistently
linked to breast cancer development in humans.
Candidate chemicals to consider as possible breast carcin-
ogens include PAH4 (8, 9), a group of compounds with two or
more conjoined aromatic rings, that are well-established mam-
mary carcinogens in rodents (3). Although some PAH com-
pounds have been categorized by the Environmental Protection
Agency as probable or possible human carcinogens (10), car-
cinogenic effects on the breast in women have not been clearly
demonstrated.
PAH compounds are ubiquitous in the environment and
major sources of human exposure are from combustion prod-
ucts of fossil fuels and cigarette smoking, and in grilled and
smoked foods (11). These compounds are lipophilic (12) and
are, thus, stored in fat tissue in humans, including breast fat.
PAH bind to DNA, and a number of methods have been
developed to measure the presence of this DNA damage in
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target tissue as well as in mononuclear cells (13, 14). Measures
of DNA adducts, therefore, reflect both exposure to PAH and
the body’s metabolic response to exposure (13).
An early ecological study reported an increase in breast
cancer rates among communities exposed to creosote, which
includes multiple compounds including PAH, through contam-
ination of the water supply (15). Several small studies (16–19)
that followed were successful in documenting a potential role
for PAH in breast carcinogenesis in women, measuring DNA
adducts using the 32P postlabeling method (20). The first two
studies(16, 17), which were based on samples of 10 and 24
subjects, respectively, demonstrated that DNA adducts are de-
tectable in a proportion of normal human breast tissue. The
third (18), based on a sample of 19 subjects, found that in about
30% of cancer cases the DNA-adduct pattern that was detected
resembled patterns that have been associated with smoking
exposure. The fourth study (19), which was based on normal
breast tissue derived from a sample size of 87 breast cancer
patients and 29 mammoplasty noncancer controls, noted a sig-
nificantly higher level of aromatic DNA adducts in the cancer
patients than in the controls. The most recent study results (21)
are based on an immunhistochemical assay (22) that used
archived tissue blocks from 100 breast cancer cases and 105
benign breast disease controls; the authors reported a 2-fold
increase in risk associated with elevated PAH-DNA adduct
levels in this New York City sample. Results of these investi-
gations are suggestive, but do not clearly establish an associa-
tion between PAH exposure and breast cancer risk, however,
because of the small number of subjects studied (which yields
unstable study results), the employment of a sensitive but
nonspecific laboratory method in most of the studies, and the
lack of a control group or controls that lacked internal consis-
tency (e.g., they did not represent the population from which
the cases arose), which could yield biased study results (23).
The study reported here is based on data collected as part
of the Long Island Breast Cancer Study Project, a large popu-
lation-based case-control investigation that was motivated by
community concerns for the effects of the environment on
breast cancer risk (24). With blood samples obtained from
newly diagnosed breast cancer cases and population-based con-
trols, PAH-DNA adducts in mononuclear cells were measured
using a competitive ELISA method (25), which is a more
feasible laboratory approach in a large-scale epidemiological
study than methods used in previous reports. An additional goal
was to explore whether the association between adduct levels
and breast cancer risk varied by cigarette smoking or grilled and
smoked food consumption, which are among the primary
sources of PAH exposure for U.S. residents.
Materials and Methods
The Long Island Breast Cancer Study Project was undertaken to
determine whether environmental factors, specifically includ-
ing exposure to PAH, are associated with breast cancer risk
among women on Long Island. This population-based, case-
control study was conducted in the counties of Nassau and
Suffolk in New York State, as mandated by Congress in 1993
(Public Law 103-43). The investigation was undertaken after
approval from participating institutional review boards and in
accordance with an assurance filed with, and approved by, the
United States Department of Health and Human Services. De-
tails of the study methods have been described previously (24).
Study Subjects. Women who were residents of Nassau and
Suffolk counties, spoke English, and were newly diagnosed
with in situ or invasive breast cancer between August 1, 1996,
and July 31, 1997, were eligible as cases. There were no age or
race restrictions. Potentially eligible cases were identified
through daily or weekly contact with the pathology departments
of the 31 institutions in the Long Island-New York City area.
Verification of the diagnosis and consent for recruitment was
obtained from the diagnosing physician for 90.5% of poten-
tially eligible case women. Potentially eligible control women,
who were frequency matched to cases by 5-year age group,
were identified using random digit dialing (RDD; Ref. 26) for
those under age 65 years, and Health Care Financing Admin-
istration (HCFA) rosters for those age 65 years or greater. For
the 59.2% of potentially eligible control women who were
under age 65 years at identification, the screening response rate
for the RDD component was 77.9%.
Interviews were completed for 1508 (82.1%) of eligible
case women and 1556 (62.7%) of eligible control women. The
primary reasons for nonresponse among cases and controls,
respectively, included refusal or break off (cases and controls:
12.4% and 21.6%, respectively) and too ill, cognitively im-
paired, or deceased (4.1% and 4.7%, respectively). Interview
response rates (see ref. 24) include, in the denominator, 25 po-
tentially eligible case women and 193 potentially eligible con-
trol women who were never located or had moved out of the
area, and, thus, final study eligibility was never determined. If
such women are omitted from the denominator, then the overall
interview response rates increase to 83.2% and 68.0%, respec-
tively. The true response rates probably lie between the two sets
of estimates. Study subjects ranged in age from 24 to 96 years,
and response to the interview varied with the age of the subject,
with 88.9% of cases and 76.1% controls under age 65 years
participating versus 71.6% and 43.3%, respectively, of those
65 years of age and older. As reported previously (24), respon-
dents ranged in age from 24 to 96 years; 93% were white, 5%
were black, and 2% were other; and 4% identified themselves
as Hispanic ethnicity, regardless of race.
Data Collection. Signed informed consent was obtained from
respondents before data collection. The main interview con-
sisted of a 2-h, interviewer-administered questionnaire. Re-
spondents were asked about their pregnancy history; occupa-
tional history; residential history; their use of pesticides in their
home or on a farm; electrical appliance use; lifetime history of
consumption of smoked or grilled foods; medical history; fam-
ily history of cancer; body size changes by decade; recreational
physical activities; cigarette smoking; alcohol use; menstrual
history; use of exogenous hormones; and demographic charac-
teristics. As reported previously (24), established risk factors
for breast cancer that were found to increase risk among Long
Island women include lower parity, late age at first birth, little
or no breast feeding, and family history of breast cancer.
Among case and control respondents who participated in
the main interview, 73.0% and 73.3%, respectively, donated a
nonfasting blood sample. Because of concern regarding ana-
lytic results based on blood samples collected after the com-
mencement of chemotherapy among cases (27), a sample of
case women with invasive breast cancer who provided a pre-
chemotherapy blood sample donated a second, postchemo-
therapy blood sample (n  155, or 98.1% of the women
approached). At the time of the blood collection, respondents
were asked to self-complete a specimen checklist that inquired
about the date of a woman’s last menstrual period (if she was
still menstruating); selected foods consumed over the past sev-
eral weeks; medications used over the past several days; ciga-
rette smoking over the past several days; and for cases, breast
cancer treatment undergone to date.
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In a previous analysis (24), established risk factors for
breast cancer that were also found to increase breast cancer risk
among Long Island residents included lower parity, late age at
first birth, little or no breast feeding, and family history of
breast cancer. Similar results were found for the analyses re-
stricted to respondents who donated blood, and for those with
DNA available for these analyses (data not shown). Factors that
were found to be associated with a decreased likelihood that a
respondent would donate blood include increasing age (1%
decrease for each yearly increase in age) and past smoking
(25% decrease); factors associated with an increased probabil-
ity include white (65% increase) or other race (74% increase),
alcohol use (28% increase), ever breastfed (47% increase), ever
use of hormone replacement therapy (63% increase), and ever
had a mammogram (51% increase). Case-control status was not
a predictor of blood donation among respondents (24).
The donated biological specimens were shipped overnight
to Columbia University in the City of New York, with the blood
samples (which were collected in lavender-top tubes) at room
temperature. Processing and aliquoting of the biological sam-
ples occurred for most subjects within 24 h of collection.
Samples were stored at 80°C and bar-code labeled with the
subjects’ randomly assigned study identification numbers, with
all laboratory personnel blinded to the case and control status of
the specimens.
Subjects Selected for Laboratory Assays of PAH-DNA Ad-
ducts. As shown in Table 1, from among the study participants
who donated a blood sample with a blood volume of greater
than 25 ml (the volume judged to be sufficient for DNA
isolation), 398 cases with invasive breast cancer and 400 con-
trols were randomly selected for the PAH-DNA analyses. In
addition, all of the samples with sufficient blood volume do-
nated by African-American subjects who were not selected
during the random selection process were assayed (n  5 cases
and 22 controls). Furthermore, all of the 129 cases diagnosed
with in situ disease who had a blood sample with sufficient
blood volume were assayed. For those randomly selected sub-
jects for whom the 100 g or more of DNA necessary to
complete the PAH analyses could not be isolated, a replacement
was randomly selected from the pool of eligible samples from
which the original sample was chosen. Non-randomly chosen
samples with sufficient blood volume (e.g., additional African
American and all in situ cases) could not be replaced. For study
efficiency, the laboratory activities began prior to the comple-
tion of data collection, and some samples were specifically
selected because they were believed to be donated by subjects
who were African-American or cases who had been diagnosed
with in situ disease. However, by the end of the field activities
when data were more complete and accurate, the selected blood
samples were determined to have been donated by whites
(1 case and 2 controls) or to have invasive disease (42 cases).
Blood samples from 120 case women with a second blood draw
had sufficient volume for DNA isolation and the PAH analyses.
Thus, satisfactory laboratory assays of PAH-DNA adducts were
completed for 575 cases (446 diagnosed with invasive breast
cancer and 129 cases with in situ breast cancer) and 424
controls. In addition, the second blood sample donated by 120
cases diagnosed with invasive breast cancer were also analyzed.
Laboratory Assays. Mononuclear cells were separated by Fi-
coll (Sigma Chemical Co., St. Louis, MO) and washed twice
with PBS. Pelleted cells were frozen at 80°C until DNA
isolation by standard phenol and chloroform isoamyl alcohol
extraction and RNase treatment. PAH diol epoxide-DNA ad-
ducts were analyzed by competitive ELISA, using methods
described previously (25, 27). Briefly, 96 microwell plates
(Corning, Acton, MA) were coated with 2 ng of BPDE-I-DNA
(5 adducts/103nucleotides). A previously characterized rabbit
antiserum (28) was used at 1:500,000 dilution. A standard curve
was constructed by mixing 50 l diluted antiserum with BPDE-
I-DNA (1.5 adduct/106nucleotides) in carrier nonmodified calf
thymus DNA such that 50 l contained 3–200 fmol BPDE-I-
deoxyguanosine adduct in 50 g of DNA. Test samples were
assayed at 50 g/well after sonication and denaturation by
boiling for 3 min and cooling on ice. Goat antirabbit IgG-
alkaline phosphatase (Boehringer Mannheim, Indianapolis, IN)
was used at 1:750 dilution, and the substrate was p-nitrophenyl
phosphate [100 l of 50 g/ml 0.1 M diethanolamine (pH 9.6).
Absorbance at 405 nm was read on a MR 5000 reader (Dyn-
atech Laboratories).
Samples were run with the laboratory blinded to case-
control status in duplicate and mean values used for the deter-
mination of percentage inhibition. For analytical purposes,
those samples with 15% inhibition were considered nonde-
tectable and assigned a value of 108, an amount midway be-
tween the lowest positive value and zero. A positive control run
with multiple batches of samples (n  11) had a mean (SD)
of 20.3 (5.0) with a CV of 25%. As an additional quality
control, 10% of samples were reassayed after recoding. There




Controls (n) Total (n)
Invasive In situ All
(A) Respondent to main questionnaire 1508 1556 3064
(B) Blood donor 1102 1141 2243
(C) Blood samples selected for PAH-DNA adduct assay ( E  F) 566 129 695 424 1119
(D) Reason for selection:
(E) Random samplea 398 128 526 400 926
(F) Specifically selected ( G  H  I  J  K) 168 1 169 24 193
(G) African American not randomly selected 5 22 27
(H) Selected as African American, but white 1 2 3
(I) Selected as in situ, but invasive 42 42
(J) Selected as invasive, but in situ 1 1
(K) Donated second sample 120 120
(L) Blood samples included in most statistical analyses ( C  K)b 446 129 575 424 999
a All of the samples donated by in situ cases with sufficient amounts of blood/DNA were selected for analyses (see “Materials and Methods”).
b Excludes second samples (see “Materials and Methods”).
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was no significant difference in mean adduct levels between the
two analyses [mean difference0.60 (SD 2.43); P 0.60
by paired t test].
Statistical Analyses. PAH-DNA adduct levels (expressed per
108 nucleotides) were log transformed on a natural scale, which
successfully normalized the observed distribution. Initial sta-
tistical analyses included comparison of the means of case and
control PAH-DNA adduct levels in blood using the unpaired
Student t test. Unconditional logistic regression (29) was used
to estimate the risk of breast cancer in relation to PAH-DNA
adduct levels, with adjustments made for the frequency-match-
ing variable age (continuous) and for other potential confound-
ing factors. Adduct levels were evaluated as a continuous
variable, as a dichotomous variable, or were categorized in
quantiles (including exploration of tertiles, quartiles, quintiles,
and deciles, with each quantile coded as a designer variable).
Covariates considered as potential confounders include: age at
menarche, parity, number of live births, lactation, months of
lactation, age at first birth, number of miscarriages, history of
fertility problems, BMI at reference, BMI at age 20, alcohol
intake, active and passive cigarette smoking, first-degree family
history of breast cancer, history of benign breast disease, oral
contraceptive use, hormone replacement use, race, ethnicity,
education, religion, marital status, season of blood donation,
total years of residence on Long Island, and age first moved to
Long Island. The final multivariate-adjusted models shown
include those factors that remained in a best fitting model,
which was developed by starting with a saturated model and
then excluding covariates that did not improve the overall fit, as
measured by the 2 log likelihood ratio test (30). Cigarette
smoking and consumption of smoked and grilled foods have
been reported as two important contributors to body levels of
PAH-DNA adducts (13). These factors were, therefore, consid-
ered as antecedents in the causal pathway for breast cancer
development and have not been included in the multivariate
models constructed to adjust for potential confounding.
To identify potential effect modification, ORs for breast
cancer in relation to detectable PAH-DNA adduct levels within
strata of selected covariates were calculated using multivariate
logistic regression models. The 2 log likelihood ratios from
unconditional logistic regression models with and without
cross-product terms were compared (30) to formally evaluate,
on a multiplicative scale, potential effect modification by cig-
arette smoking (never/ever passive only/ever active only/ever
active  passive), recent consumption of grilled and smoked
foods (beef  lamb  pork  poultry  fish intake within the
most recent decade, continuous), alcohol intake (ever/never),
menopausal status (pre-/postmenopausal), length of residence
on Long Island (15 years/15 years), and age at reference
date (65 years/65 years). To determine the risk of breast
cancer with cases categorized by stage of disease (in situ or
invasive), or by ER and PR status, unordered polytomous
logistic regression (30) was performed.
Cigarette smoking definitions are based on self-reported
data from the main questionnaire, which queried each subject
about her exposures before the reference date (the date of
diagnosis for cases and date of identification for controls), and
the specimen checklist, which queried the respondent about
their exposures in the past few days (and thus assessed exposure
after the reference date). A current active cigarette smoker was
defined as a regular smoker within the last 12 months before the
reference date; a former active smoker was defined as a regular
smoker who reported quitting more than 12 months before the
reference date; a passive smoker was defined as either a current
or former smoker or nonsmoker who reported ever living with
an active smoker; and a never smoker was a nonsmoker who
also did not report living with an active smoker. Discrepancies
between the checklist and main questionnaire were infrequent.
If a subject was categorized as a never or former smoker based
on the main questionnaire, but on the checklist reported smok-
ing (n  9) or data were missing (n  9), the subjects was
omitted from the PAH analyses. Further, if the subject was
categorized as a current smoker on the main questionnaire, but
on the checklist reported not smoking in the past few days (n
30) or data were missing (n  1), then the subject was main-
tained in the PAH analyses as a current smoker.
Definitions of consumption of grilled and smoked foods
were constructed based on data collected in the main question-
naire, which focused on historical consumption by decade be-
fore the reference date, and in the specimen checklist, which
focused on consumption in the 4 weeks before blood collection.
In the main questionnaire, women were queried about their
consumption patterns over 6 decades of life (20 years, 20–29
years, 30–39 years, 40–49 years, 50–59 years, 60 years) for
four different groups of PAH-containing foods: smoked beef,
lamb, and pork; grilled or barbecued beef, lamb, and pork;
smoked poultry or fish; and grilled or barbecued poultry or fish.
The average of the 6 decades was calculated to derive an
average lifetime consumption of the four PAH food groups. For
each of the 24 groups (6 decades of consumption  four food
groups), values were missing for less than 2% of respondents;
and for the four derived averages, values were missing for
9–10% of respondents. The vast majority of missingness was
restricted to a single decade of reported consumption. Imputa-
tions for the missing values were derived by multiple regression
(29) using data from subjects with complete data to predict the
missing variables in each of the 24 groups. In addition, because
of concerns about possible cohort effects, regressions were
performed separately by the decade of age at interview. There-
fore, for example, to predict average consumption of smoked
beef, lamb, and pork between ages 20–29 years, for women in
their 30s at reference, multiple regression was conducted using
subjects in their 30s at reference to construct a model: beef
consumption during ages 20–29 years   (constant)  1
(beef consumption under age 20 years) 2 (beef consumption
during ages 30–39 years)   (error). The regression coeffi-
cients, 1 and 2, were then used to impute beef consumption
for all subjects in their 30s who were missing only beef con-
sumption during the decade 20–29 years of age. These steps
were repeated for other subjects missing only one interval of
consumption within each food category. To correct for artifi-
cially minimized SEs for the ORs produced when using impu-
tations, the SEs obtained using imputed data were inflated back
to the lower sample-size level. This imputation strategy reduced
the amount of missing consumption data in the following man-
ner: lifetime grilled or barbecued beef, lamb, or pork consump-
tion from 9.48% to 2.68%; lifetime intake of grilled or barbe-
cued poultry or fish from 9.60% to 3.27%; lifetime smoked
beef, lamb or pork consumption from 8.55% to 2.75%; lifetime
intake of smoked poultry or fish from 9.77% to 4.72%; and
lifetime consumption of all four types of food combined from
14.77% to 5.24%. The ORs obtained from this imputed data set
were not materially different from those obtained from the data
set in which missing consumption values were simply dropped,
although, as expected, CIs were wider for the latter data set
(data not shown). Sensitivity analyses revealed that substitution
of more crudely derived imputations, e.g., either the highest or
lowest observed values, did not substantially affect the ob-
served ORs (data not shown). Thus, the results based on models
680 PAH-DNA Adducts and Breast Cancer
with the more precisely estimated regression coefficients im-
puted for the missing values are shown.
A subject was defined as postmenopausal if her last men-
strual period was more than 6 months before the reference date
or if she had both ovaries removed before the reference date
(24). If a subject was taking hormone replacement therapy or
had a hysterectomy without removal of both ovaries, her men-
opausal status was initially classified as unknown (11.81% of
subjects). To reduce the number of subjects with unknown
menopausal status, we used information about the subject’s
reference age. That is, any smoker with unknown menopausal
status was categorized as postmenopausal if her age at reference
was54.8 years (90% percentile for natural menopause among
smoking controls), and any nonsmoker with unknown meno-
pausal status was categorized as postmenopausal if her age at
reference was 55.4 years (90% percentile for natural meno-
pause among nonsmoking controls).
The statistical analyses are based on 575 cases (398 who
were randomly selected and 171 who were specifically se-
lected) and 424 controls (400 who were randomly selected and
24 who were specifically selected). The analyses were repeated
restricting the study sample to those 398 cases and 400 controls
that were randomly chosen to have their blood samples assayed
for the PAH-DNA adducts. Results from these latter models
were nearly identical to the former, and are not shown.
Results
Among the 575 cases and 424 controls who donated a blood
sample and who were selected for the PAH-DNA analyses,
mean PAH-DNA adducts per 108 nucleotides (and correspond-
ing SD) were 16.5 (24.2) for cases and 15.1 (24.2) for controls;
the median (and range) for cases and controls were 9.03 (1.00–
278.64) and 8.17 (1.00–246.97), respectively. Means (and SD)
of the log-transformed data (on a natural scale) were 2.00 (1.39)
and 1.83 (1.43) per 108 nucleotides among cases and controls,
respectively; the corresponding geometric means and geometric
SD were 7.36 (7.29) for cases and 6.21 (4.17) for controls. The
observed difference in the log means was not statistically sig-
nificant (P  0.51). All of the additional analyses are based on
the log-transformed data.
Table 2 shows the age-adjusted and multivariate-adjusted
ORs for breast cancer in relation to PAH-DNA adduct levels
categorized in quantiles according to the distribution among
controls, with all nondetectable levels placed in the lowest
quantile as the referent. Among those with the highest quintile
of exposure, as compared with the lowest quintile, the age-
adjusted OR was 1.51 (95% CI, 1.04–2.20). There was no
further substantial elevation in risk when PAH-DNA adduct
levels were categorized in deciles rather than quintiles (data not
shown). Because of the large number of women for whom no
detectable levels of adducts were observed, we estimated the
risk associated with having detectable adduct levels (age-
adjusted OR, 1.32; 95% CI, 1.00–1.74, for detectable versus
nondetectable levels). Repeating the analyses with the sample
restricted to those subjects with detectable levels of adducts,
which can be interpreted as an indicator of the dose-response
among the exposed, the ORs showed little or no increasing risk
with increasing adduct formation; for the highest quantile of
five categories as compared with the lowest, the OR was 1.13
(95% CI, 0.71–1.81). As shown in Table 2, there was no
substantial confounding of the association between PAH-DNA
adduct levels and breast cancer risk.
Table 3 shows the multivariate-adjusted ORs for breast
cancer in relation to detectable PAH-DNA adducts (1.35 as
compared with no detectable levels, 95% CI, 1.01–1.81) and
stratified by factors that have potential to modify the associa-
tion. The multivariate adjusted ORs for breast cancer shown are
in relation to detectable adduct levels as compared with non-
detectable levels within strata of the potential effect modifier.
Risk of breast cancer in relation to detectable adducts did not
appear to significantly vary by: menopausal status; the subjects’
length of residence on Long Island; whether the study subjects
were younger than 65 years of age at reference or 65 years of
age and older; or whether the case was diagnosed with in situ
or invasive disease. Consideration of other cut points for years
of residence on Long Island did not materially differ from the
results reported (data not shown). Risk significantly varied
when cases were categorized by the ER and PR status of the
tumor, with an 60% increase in risk among women with
ERPR and ERPR tumors and no elevation in risk
among those with discordant ERPR status.
Differences between case and control levels of PAH-DNA
adducts [geometric means (geometric SDs)] also did not vary
substantially with whether the blood sample from the same
subjects (n  103 pairs) was collected before [7.22 (4.19)] or
after [8.36 (3.67)] the commencement of chemotherapy (P 
0.45). Thus, when restricting the analyses to controls and cases
who had donated a prechemotherapy sample only (n  381
cases), the ORs (and 95% CI) for breast cancer in detectable
PAH-DNA adducts did not vary substantially from the analyses
that included case subjects with either pre- or postchemo-
therapy samples available (data not shown).
Grilled and smoked foods as well as cigarette smoking are
reported as important sources of PAH (11). In these data,
however, adduct levels among control women did not increase
with increasing lifetime average intake of grilled or smoked
foods: geometric mean adduct levels per 108 nucleotides (and
geometric SD) were 7.90 (3.80) for quintile 1; 5.44 (4.12) for
quintile 2; 7.67 (4.36) for quintile 3; 6.01 (4.27) for quintile 4;
and 5.71 (4.04) for quintile 5 (ANOVA P  0.32). In addition,
mean levels were not associated with consumption of grilled or
smoked foods during the 4 weeks before donation of the blood
Table 2 Adjusted ORs for breast cancer and 95% CIs in relation to PAH-DNA adduct levels, Long Island Breast Cancer Study Project, 1996–1997
Quantile of PAH-DNA adduct level per 108





Quantile 1 (nondetects) 148 134 1.00 1.00
Quantile 2 (0 to 7.7237) 105 72 1.31 (0.89–1.92) 1.45 (0.97–2.17)
Quantile 3 (7.7237 to 14.4212) 112 73 1.36 (0.93–1.98) 1.48 (0.99–2.21)
Quantile 4 (14.4212 to 21.9357) 88 73 1.09 (0.74–1.62) 1.01 (0.67–1.52)
Quantile 5 (21.9357) 122 72 1.51 (1.04–2.20) 1.49 (1.00–2.21)
a Adjusted for age at reference date (continuous), race, history of infertility problems, season of blood donation, religion, parity (continuous), total months of lactation
(continuous), BMI at age 20 (continuous), first-degree family history of breast cancer, age at first birth (centered, continuous).
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sample (data not shown). As shown in Table 4, geometric mean
PAH-DNA adduct levels among controls also did not vary with
current or former active cigarette smoking [6.31 (4.38) for
never; 5.92 (3.93) for former; and 6.52 (4.24) for current;
ANOVA P  0.87] or, when passive smoking exposure was
considered [7.96 (4.46) for never active or passive; 5.87 (4.31)
for ever passive only; 4.95 (3.96) for ever active only; and
6.33 (4.04) for ever active and passive; ANOVA P  0.48].
Table 4 also shows the multivariate-adjusted ORs for
breast cancer in relation to detectable PAH-DNA adducts strat-
ified by cigarette smoking, alcohol intake, or grilled or smoked
food consumption in the most recent decade of life, before the
reference date. The ORs shown are for detectable PAH-DNA
adduct levels as compared with no detectable levels within the
strata of smoking or smoked food consumption. There was little
variation in the ORs in relation to adduct levels with active or
passive smoking status, alcohol intake, or by quintile of grilled
and smoked food consumption.
Discussion
The carcinogenicity of PAH, such as DMBA, on the mammary
gland of laboratory animals has been well demonstrated (31),
but their role in breast cancer development in women has not
been well studied. PAH are bulky carcinogens, and elevated
levels of PAH-DNA adducts have been observed in lung cancer
cases (32). Furthermore, patterns of p53 mutations seen in the
breast resemble those seen in the lung (33). Thus, it is possible
that PAHs are breast carcinogens in humans as they are in
animal models. In contrast, it is also possible that PAH may
have antiestrogenic potential (34), as has been postulated for
cigarette smoking (35), which is one of the major sources of
PAH exposure in American populations (11, 13). However, it is
also unclear whether cigarette smoking has carcinogenic effects
or antiestrogenic effects on the breast (36, 37). Because of the
biological plausibility of dual effects of PAH on the breast,
utilization of a biological marker, such as DNA adducts, that
reflects internal dose may help to clarify the issue.
This study is the first large-scale epidemiological study to
evaluate whether DNA damage associated with PAH exposure
increases the risk of breast cancer. In this population-based,
case-control study among women on Long Island, a modest
50% elevation in the risk of breast cancer was noted in relation
to the highest quintile of PAH-DNA adduct levels; however, no
dose-response effect was observed. These results, coupled with
the observed 50% increase in risk noted among women with
detectable adducts, suggests that there may be a threshold
effect. Results were not strongly confounded by known or
suspected risk factors for breast cancer.
Mean PAH-DNA adduct levels among control women did
not vary with active or passive cigarette smoking status or
within levels of grilled or smoked food consumption, which are
reported to be among the largest sources of PAH among Amer-
icans. This lack of an association between adduct levels and the
major sources of PAH adducts suggest perhaps that the adducts
are better indicators of the body’s response to the carcinogenic
insult, rather than an indicator of exposure level. In other
words, the presence of high levels of PAH-DNA adducts may
be indicative of a susceptible individual.
We also found elevated risks for breast cancer in relation to
adduct levels associated with ERPR tumors as well as
ERPR tumors, but not for those with discordant receptor
status. Smoking has been previously reported to be associated with
p53 breast cancer (37), and p53 expression and ER are con-
sistently found to occur together (38, 39). In previous studies,
smoking has been found to increase the risk of ER tumors, but
not ER tumors (40, 41). Thus, our observation of an increase risk
with PAH among concordant ERPR status tumors, regardless of
whether the status of the receptor was positive or negative, is not
entirely consistent with other reports. However, our observation
for an50% elevation in breast cancer risk associated with DNA
adducts is consistent with two previously reported epidemiological
studies (19, 21), with one of them showing a doubling in risk (21).
A number of issues that may affect interpretation of our findings
are discussed below.
Table 3 Adjusted ORs for breast cancer and 95% CIs in relation to detectable PAH-DNA adduct levels stratified by menopausal status, length of residence in
interview home, age at diagnosis, stage, and estrogen receptor and progesterone receptor status. Long Island Breast Cancer Study Project, 1996–1997
Stratifying factor
Mean (SD) PAH-DNA adduct levelsa
Case, n Control, n Multivariate-adjusted
b OR
(95% CI)cCases Controls
Main effect 16.52 (24.18) 15.14 (24.21) 575 424 1.35 (1.01–1.81)
Menopausal status
Premenopausal 16.23 (28.10) 14.19 (22.28) 180 142 1.58 (0.94–2.66)
Postmenopausal 16.20 (21.66) 15.92 (25.82) 352 248 1.19 (0.82–1.72)
Length of residence in interview home
15 yr 17.42 (24.14) 14.30 (23.58) 65 49 1.74 (0.71–4.26)
15 yr 16.59 (24.49) 14.93 (23.15) 468 344 1.30 (0.95–1.80)
Age at diagnosis
65 yr 16.32 (24.02) 14.12 (20.69) 370 317 1.48 (1.05–2.09)
65 yr 16.91 (24.56) 18.74 (33.67) 178 90 1.18 (0.64–2.18)
Stage
In situ 17.41 (22.66) 15.14 (24.21) 129 424 1.50 (0.93–2.42)
Invasive 16.26 (24.62) 15.14 (24.21) 446 424 1.32 (0.97–1.79)
ER and PR status
ER/PR 19.73 (29.93) 15.14 (24.21) 218 424 1.59 (1.06–2.37)
ER/PR 14.24 (25.09) 15.14 (24.21) 52 424 0.92 (0.46–1.85)
ER/PR 17.82 (23.93) 15.14 (24.21) 18 424 0.92 (0.32–2.60)
ER/PR 14.42 (15.66) 15.14 (24.21) 68 424 1.64 (0.87–3.10)
a PAH-DNA adduct levels are presented untransformed.
b Adjusted for age at reference date (continuous), race, history of infertility problems, season of blood donation, parity (continuous), total months of lactation (continuous),
BMI at age 20 (continuous), first-degree family history of breast cancer, age at first birth (centered, continuous).
c PAH-DNA adduct levels have been log transformed prior to logistic regression analyses (see “Materials and Methods.”).
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Subject Selection. Response rates were lower among controls
than in cases, especially among women over age 75 years (24).
This study had no upper age limit, and comorbidity among the
elderly controls and the protective efforts of the subjects’ fam-
ilies limited study participation among these older women. If
the older respondents in the our study somehow differ system-
atically from nonrespondents, our results may not be general-
izable to older women.
As reported previously (24), the distribution of known
risk factors for breast cancer differed among blood donors
and nondonors. Factors that were found to be associated with
a decreased likelihood that a respondent would donate blood
included increasing age and past smoking; factors associated
with an increased probability included white or other race,
alcohol use, ever breastfed, ever use of hormone replacement
therapy, ever use of oral contraceptives, and ever had a
mammogram (24). Thus, there is the possibility that bias
may have affected our results, although the few factors
identified as potential confounders were not related to the
factors found to influence the probability of donating a
sample. Furthermore, the proportion of eligible subjects who
were willing to donate blood was comparable with that
reported by other population-based studies with a phlebot-
omy component (42). Thus, the sample reported here is
likely to be similar to a population from other similarly
designed epidemiological studies.
Table 4 Adjusted ORs for breast cancer and 95% CIs in relation to detectable PAH-DNA adduct levels stratified by cigarette smoking, alcohol, and by consumption
of grilled and smoked foods in most recent decade of life, Long Island Breast Cancer Study Project, 1996–1997
Stratifying Factor
Mean (SD) PAH-DNA adduct levelsa
per 108 nucleotides Case, n Control, n
Multivariate-adjustedb ORs
(95% CI) for detectable
PAH-DNA adduct levelscCases Controls
16.52 (24.18) 15.14 (24.21) 575 424 1.35 (1.01–1.81)
Active cigarette smoking exposure
Never 16.17 (24.99) 16.89 (29.53) 235 190 1.39 (0.90–2.15)
Former 18.33 (26.75) 12.94 (17.05) 209 154 1.44 (0.88–2.38)
Current 13.69 (15.08) 15.09 (20.76) 104 62 1.28 (0.62–2.64)
Active and/or passive cigarette smoking
Never either 12.00 (13.87) 18.79 (24.80) 43 42 0.51 (0.17–1.50)
Ever passive only 17.16 (26.95) 16.22 (30.95) 188 146 1.63 (0.99–2.70)
Ever active only 17.99 (30.33) 11.95 (20.70) 41 32 3.06 (0.66–14.12)
Ever both 16.22 (22.25) 13.97 (18.02) 263 177 1.22 (0.78–1.89)
Alcohol intake
Never 7.23 (4.08) 6.34 (4.33) 173 147 1.42 (0.86–2.36)
Ever 7.42 (3.98) 6.14 (4.09) 375 260 1.37 (0.95–1.98)
Intake of grilled/BBQd beef, lamb, and pork in most recent decade of life
Quantile 1 15.06 (23.68) 14.80 (20.48) 122 87 0.69 (0.35–1.35)
Quantile 2 16.49 (17.93) 15.82 (23.02) 91 58 1.43 (0.64–3.20)
Quantile 3 18.50 (24.67) 18.33 (30.57) 123 101 1.29 (0.68–2.42)
Quantile 4 15.00 (15.75) 16.09 (29.19) 89 78 1.78 (0.83–3.85)
Quantile 5 17.39 (33.09) 10.61 (10.88) 115 76 1.26 (0.64–2.49)
Intake of grilled/BBQ poultry and fish in most recent decade of life
Quantile 1 15.46 (22.06) 15.29 (20.08) 145 104 0.66 (0.35–1.26)
Quantile 2 14.50 (16.57) 15.00 (17.07) 112 88 1.42 (0.70–2.89)
Quantile 3 18.23 (23.78) 21.01 (41.61) 76 51 1.50 (0.64–3.53)
Quantile 4 15.24 (16.66) 14.60 (27.22) 89 67 2.09 (0.91–4.80)
Quantile 5 19.43 (35.81) 13.00 (18.76) 115 89 2.02 (1.08–3.78)
Intake of smoked beef, lamb, and pork in most recent decade of life
Quantile 1 17.59 (22.35) 15.20 (21.17) 195 148 1.34 (0.78–2.31)
Quantile 2 15.52 (17.63) 17.17 (34.82) 80 47 1.61 (0.69–3.77)
Quantile 3 12.47 (16.69) 15.04 (20.77) 101 90 1.87 (0.94–3.70)
Quantile 4 20.48 (44.06) 21.71 (38.84) 48 41 0.23 (0.06–0.93)
Quantile 5 17.08 (25.17) 10.94 (13.44) 117 77 1.88 (0.97–3.64)
Intake of smoked poultry and fish in most recent decade of life
Quantile 1 16.33 (22.44) 15.97 (23.35) 355 267 1.45 (1.00–2.09)
Quantile 2 15.48 (17.58) 20.11 (47.92) 44 25 0.82 (0.18–3.64)
Quantile 3 17.57 (34.64) 11.37 (15.23) 87 64 1.39 (0.68–2.83)
Quantile 4 23.83 (32.89) 7.20 (7.38) 15 18 14.62 (0.75–284.21)
Quantile 5 14.18 (13.85) 14.65 (19.59) 40 27 0.34 (0.05–2.23)
Intake of all PAH foods in most recent decade of life
Quantile 1 17.04 (23.49) 15.58 (20.64) 100 70 0.80 (0.35–1.83)
Quantile 2 14.79 (18.54) 12.42 (16.20) 108 82 1.42 (0.72–2.79)
Quantile 3 14.45 (19.09) 24.44 (41.45) 101 80 0.75 (0.38–1.49)
Quantile 4 18.05 (22.66) 14.94 (19.81) 108 82 2.53 (1.17–5.45)
Quantile 5 18.01 (34.54) 9.90 (10.19) 110 78 1.28 (0.67–2.45)
a PAH-DNA adduct levels are presented untransformed.
b Adjusted for age at reference date (continuous), race, history of infertility problems, season of blood donation, religion, parity (continuous), total months of lactation
(continuous), BMI at age 20, first-degree family history of breast cancer, age at first birth (centered, continuous).
c PAH-DNA adduct levels have been log transformed prior to logistic regression analyses (see “Materials and Methods”).
d BBQ, barbecued.
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Exposure Measurement. The most optimal laboratory
method to measure PAH-DNA adducts is controversial. Al-
though the ELISA technique used in our study requires 25–35
ml of blood, a volume larger than the 10 ml or less required for
the postlabeling method, the assay is more quickly conducted,
which enhances its use in large epidemiological studies. In
addition, laboratory personnel are not exposed to radiation.
More importantly, the antiserum used recognizes benzo-
(a)pyrene and structurally related PAH diol epoxide-DNA ad-
ducts. Furthermore, the method was successful in identifying
increased levels of adducts among lung cancer cases (33). In
contrast, the smaller blood volume required for postlabeling is
more advantageous for human subject research. In addition, the
method is more sensitive than the ELISA because of the high
specific activity of 32P. However, postlabeling is not specific
for PAH and is a more tedious laboratory assay, which restricts
its usefulness for large-scale research. Another available option
is the assessment of adducts in archived tissue by immunohis-
tochemical methods. Although this method has the advantage
of detection of adducts in the target tissue, one (22) of the two
previous studies (21, 22) that has used immunohistochemical
methods to detect PAH-DNA adducts in breast tissue was
unable to document an association between adduct levels and
smoking. Also, control selection in a study that uses the im-
munohistochemical method of adduct assessment is necessarily
restricted to those from whom target tissue can be obtained,
which is generally not the source population from which the
cases arose; such selection methods can result in study bias
(23). It is reassuring to note that, regardless of the method used
to detect PAH compounds, our findings, which are based on a
large population-based sample of breast cancer cases and con-
trols, are similar to those observed in earlier smaller hospital-
based reports (19, 21).
The time frame of exposure measured by the adduct levels
is unclear and may vary from a few months to a few years. In
earlier studies of lung cancer, total WBCs, with a cell turnover
of several months, were used to measure the DNA adducts.
With the current use of mononuclear cells, with a cell life as
long as 3 years, as the source of DNA for the assay, the relevant
exposure time may be longer, but the actual relevant time frame
is uncertain. Thus, as in many environmental epidemiology
studies, measurement of current levels of an environmental
contaminant are assumed to reflect past exposures. Unfortu-
nately, no biomarkers are currently available that reflect long-
past exposures to PAH. Current levels of PAH-DNA adducts,
however, may be relevant to breast carcinogenesis if PAH
affect mechanisms related to later stages of cancer, such as
mutations in tumor suppressor genes, like p53. Adducts meas-
ured at diagnosis are unlikely to be related to earlier, tumor-
initiating events, given the long latency of breast cancer.
Measurement of two of the major sources of PAH, ciga-
rette smoking and consumption of grilled and smoked foods,
was comprehensive. Assessment of smoking included both
active and passive smoking exposures. However, because of
time constraints in the main questionnaire, respondents were
queried about their lifetime residential or leisure time, but not
occupational, passive smoking exposures. Lifetime grilled and
smoked food intake was assessed by asking women about their
intake of these foods by decade of life. It is, therefore, unlikely
that the lack of an association between PAH-DNA adduct levels
and smoking or grilled and smoked food intake is associated
with poor measurement of these exposures, although exposure
misclassification cannot be ruled out. It is possible that the
PAH-DNA adduct levels observed in this study (a) are associ-
ated with other unmeasured sources of PAHs [such as air
pollution, or leafy green vegetables in the diet (43)]; (b) are
associated with some other exposures that may be highly cor-
related with PAH such as heterocyclic amines; or (c) are a
surrogate for some other unmeasured factor. Alternatively, the
lack of association between measured PAH sources of smoking
and diet and adduct levels in these data may reflect variability
in individual susceptibility. For example, among those persons
with similar exposure levels such as smokers, the subject’s
individual response to the insult, through individual variation in
DNA repair or other mechanisms, influences breast cancer
development. To evaluate potential gene-environment inter-
actions, laboratory assays are under way on polymorphisms
involved in oxidative stress and DNA repair.
In conclusion, consistent with animal evidence that dem-
onstrates the mammary carcinogenicity of PAH compounds, in
this population-based study of women on Long Island an50%
increase in breast cancer risk was noted in relation to PAH-
DNA adducts, which are indicative of recent DNA damage. Our
results are also consistent with two previous smaller epidemi-
ological studies (19, 21), which noted higher levels of adducts
among breast cancer cases as compared with hospital-based
controls. No trend in risk was observed, which is suggestive of
a threshold effect. We did not observe a relation between
PAH-DNA adduct levels and several major sources of PAH,
including cigarette smoking or intake of grilled and smoked
foods, which is in contrast to several previous small investiga-
tions. However, these findings may suggest that individual
differences in the response to similar levels of PAH exposure
may be more relevant in breast carcinogenesis. PAH-DNA
adducts reflect only recent exposures; therefore, future research
in this area should focus on PAH exposure in the more distant
past, which is likely to be more useful when assessing breast
cancer risk. Biomarkers are not available that reflect exposures
in the distant past, and other exposure assessment methods,
such as geographic modeling (44), may need to be used when
evaluating the breast carcinogenic potential in humans.
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